All In Biotech

Drug Trial Radar · NCT05800327

A Two-Stage Study of the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics and Immunogenicity of Various Doses of Levilimab When Administered Intravenously and Subcutaneously to Healthy Subjects and Subjects With Active Rheumatoid Arthritis

Last checked: Nov 19, 2026Latest source record: Apr 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 261 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

261

Planned (sponsor's estimate)

Start

Dec 7, 2022

Primary completion

Sep 2024

Study completion Dec 2027

Sponsor

Lead sponsor
BiocadIndustry
Sponsor type
Industry
First posted
Apr 5, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a two-stage study of efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of various doses of levilimab when administered intravenously and subcutaneously to healthy subjects and subjects with active rheumatoid arthritis resistant to methotrexate monotherapy. Aim of the Stage 1 is to study the tolerability, safety, immunogenicity, and main pharmacokinetic and pharmacodynamic parameters of levilimab after its single subcutaneous or intravenous administration at ascending doses to healthy subjects. Aim of the Stage 2 is to confirm the efficacy and safety of levilimab 648 mg IV Q4W in combination with methotrexate and levilimab 324 mg SC Q2W in combination with methotrexate in subjects with active rheumatoid arthritis, resistant to methotrexate monotherapy.

Conditions

  • Rheumatoid Arthritis

Interventions

  • LevilimabDrug

    Subcutaneous or intravenous injection of levilimab with placebo.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety primary endpoint (Stage 1)Time frame: Up to day 71
  2. Low disease activity (Stage 2)Time frame: Up to Week 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • X7 Clinical Research

    Saint Petersburg, Russia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.